Human Cancer Virology Research Program

UWCCC人类癌症病毒学(VR)项目摘要 联合领导人：保罗·F·兰伯特和香农·肯尼 项目摘要/摘要 人类肿瘤病毒与超过15%的人类癌症有因果关系，并可能导致 其他癌症。人类癌症病毒学(VR)计划的使命是促进对癌症的了解， 通过基础研究预防和治疗病毒相关癌症和其他癌症。该计划 有14名高度协作的成员，他们分布在威斯康星州大学校园的7个部门和3所学校；4名是总经理 他们经营着研究实验室并在系里实习。医学或外科的，带来有价值的临床前景 加入到项目中。VR项目成员研究了7种已建立的人类肿瘤病毒中的6种，以及 HIV/SIV。自本资助期开始以来，村代表会员出版了196份出版物 (包括大量关于PNAS、JCI、细胞宿主微生物、PLOS病原体和其他高影响的论文 期刊)，或在本供资期间每个成员平均出版16种出版物。在这些出版物中， 约21.5%是方案间协作，约11%是方案内协作。在这一年 仅2016年一年，就有近46%的出版物是与其他机构合作的。VR计划的14名成员 资金充足，有446万美元的直接同行评审奖励(48%来自NCI)和其他资金来源 (例如，保罗·阿尔奎斯特的摩格里奇学院，内森·谢勒的UW2020项目)。在上一个资金周期中， VR计划成员续签了长期存在的NCI计划项目拨款，用于肿瘤病毒和 在头颈癌中获得新的孢子方面发挥了核心作用。UWCCC人类的目标 癌症病毒学计划(VR)涵盖了UWCCC战略运营计划的所有方面，包括：1) 阐明各种肿瘤病毒感染、复制、与宿主相互作用和维持的途径 它们在几年到几十年中的存在通常与肿瘤的发展和进展有关；2) 确定肿瘤病毒促进肿瘤诱导和维持的机制，包括 确定肿瘤细胞持续存活所必需的病毒和宿主基因；以及3)确定分子 病毒感染和肿瘤的变化和诊断/预后生物标志物及其应用 开发新的、改进的方法来预防和治疗肿瘤病毒感染、复制、肿瘤的见解 诱导和维护。

UWCCC Human Cancer Virology (VR) Program Summary Co-Leaders: Paul F. Lambert and Shannon Kenney PROJECT SUMMARY/ABSTRACT Human tumor viruses are causally associated with over 15% of all human cancers and are likely to contribute to additional cancers. The mission of the Human Cancer Virology (VR) Program is to advance the understanding, prevention, and treatment of virus-associated cancers and other cancers through basic research. The program has 14 highly collaborative members who span 7 departments and 3 schools on the UW campus; 4 are MDs who run research labs and practice in the Dept. of Medicine or Surgery, bringing valuable clinical perspectives to the program. The VR program members study 6 of the 7 established human tumor viruses as well as HIV/SIV. Since the beginning of the current funding period, the VR members have published 196 publications (including numerous papers in PNAS, JCI, Cell Host Microbe, PLOS Pathogens, and other high impact journals), or on average 16 publications per member over the current funding period. Of these publications, ~21.5% were inter-programmatic collaborations and ~11% were intra-programmatic collaborations. In the year 2016 alone, nearly 46% of publications were collaborative with other institutions. The 14 VR Program members are well funded with $4.46M Direct peer-reviewed awards (>48% from NCI) and additional funding sources (e.g. Morgridge Institute for Paul Ahlquist, UW2020 Program for Nathan Sherer). In the last funding cycle, members of the VR program renewed the long-standing NCI program project grant on tumor viruses and played a central role in obtaining a new SPORE in head and neck cancer. The aims of the UWCCC Human Cancer Virology Program (VR), which span all aspects of the UWCCC Strategic Operating Plan, are to: 1) elucidate the pathways by which diverse tumor viruses infect, replicate, interact with their hosts, and maintain their presence through the years to decades typically associated with tumor development and progression; 2) determine the mechanisms by which tumor viruses promote tumor induction and maintenance, including identifying viral and host genes essential to the continuing survival of tumor cells; and 3) define molecular changes and diagnostic/prognostic biomarkers of virally induced infections and neoplasia and use these insights to develop novel, improved approaches to prevent and treat tumor virus infection, replication, tumor induction and maintenance.